For example, preclinical studies have shown that infrequent, low-dose administration of TLR7/8 agonists can better induce tumor elimination compared to frequent administrations.628,629 Additionally, more effective immune activation can be achieved by sequentially stimulating receptors that do not exhibit cross-tolerance. Here, TLR7 is linked to neoplasm.